Zivo Bioscience, Inc.
ZIVO
$17.80
-$0.10-0.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 166.95% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 166.95% | -- | -- | -- | -- |
| Cost of Revenue | 187.01% | -- | -- | -- | -- |
| Gross Profit | 131.71% | -- | -- | -- | -- |
| SG&A Expenses | 43.31% | 331.54% | -37.80% | -25.02% | -2.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.65% | 350.22% | -33.43% | -27.65% | -20.79% |
| Operating Income | -43.73% | -351.21% | 35.25% | 28.10% | 21.38% |
| Income Before Tax | -24.31% | -297.78% | 35.20% | 27.73% | 8.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.31% | -297.78% | 35.20% | 27.73% | 8.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.31% | -297.78% | 35.20% | 27.73% | 8.95% |
| EBIT | -43.73% | -351.21% | 35.25% | 28.10% | 21.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 36.73% | -110.86% | 62.99% | 41.13% | 17.65% |
| Normalized Basic EPS | 36.74% | -110.87% | 62.99% | 41.13% | 17.65% |
| EPS Diluted | 36.73% | -110.86% | 62.99% | 41.13% | 17.65% |
| Normalized Diluted EPS | 36.74% | -110.87% | 62.99% | 41.13% | 17.65% |
| Average Basic Shares Outstanding | 96.46% | 88.65% | 75.06% | 22.78% | 10.57% |
| Average Diluted Shares Outstanding | 96.46% | 88.65% | 75.06% | 22.78% | 10.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
